The enrollment completion is a positive operational milestone, but the stock may have limited near-term catalyst until top-line data in mid-2027. Monitor for any Data Safety Monitoring Board updates or early signals. Traders should weigh the long timeline against the large addressable market.
Drug in focus
MESO drug pipeline →rexlemestrocel-L
▲ Bullish Named in this 6-K- Impact
- Phase
- Phase 3 / Filed BLA
- Time to market
- LVAD/heart failure BLA now under FDA review with modular review requested — no PDUFA date set yet (potentially 2027 if accepted). CLBP indication likely 2028 at earliest (topline mid-2027, BLA Q3 2027, FDA action 2028).
- Next catalyst
- None dated
What to watchMesoblast just filed a BLA for rexlemestrocel-L in LVAD/heart failure, the next catalyst is FDA acceptance and a PDUFA date. Meanwhile, the much larger CLBP opportunity (7M+ US patients, non-opioid approach) is advancing with Phase 3 enrollment complete and topline due mid-2027. The company already generates real revenue from Ryoncil (~$110-120M FY2026 guidance), de-risking the story vs. pre-revenue biotechs. Monitor (1) FDA's action on the LVAD BLA modular review, (2) CLBP Phase 3 topline in mid-2027, and (3) Ryoncil revenue growth trajectory.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 14 $16.74entry
- T+1 · 4mo ago +8.96%α +8.56% · $18.24
- T+5 · 4mo ago −0.66%α +0.64% · $16.63
- T+20 · 3mo ago +1.08%α −1.42% · $16.92
- T+60 · 6w ago −16.73%α −20.10% · $13.94
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Mesoblast announced it has enrolled the target of 300 patients in the pivotal Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease. Top-line results are expected in mid-CY2027. The trial has RMAT designation from the FDA, and the company is proceeding with commercial manufacturing in parallel. This milestone de-risks the program but does not provide efficacy data.
Key Facts
- At least 300 patients treated in the placebo-controlled pivotal Phase 3 trial of rexlemestrocel-L for CLBP.
- Top-line results expected in mid-CY2027 after the last patient completes 12-month follow-up.
- Rexlemestrocel-L has FDA RMAT designation, providing eligibility for priority review upon BLA filing.
- Management estimates potential peak year revenue of >$10 billion with single-digit market penetration (forward-looking statement).
- The trial is powered to show significant difference in pain reduction at 12 months vs. sham control.
Financial Impact
No current financial data filed. Management projects potential peak revenue >$10B for this indication, but this is a forward-looking estimate.
Risk Factors
- Trial failure to meet primary endpoint could severely impair the program.
- Regulatory delays or additional data requirements from FDA.
- Competition from other non-opioid pain treatments.
- Dilution risk if Mesoblast needs to raise capital to fund commercial launch.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001345099-26-000066 |
| Exhibit: exhibit991clbppivotaltri.htm | 0001345099-26-000066 |
| Document: 0001345099-26-000066-index-headers.html | 0001345099-26-000066 |
| Document: 0001345099-26-000066-index.html | 0001345099-26-000066 |
| Document: 0001345099-26-000066.txt | 0001345099-26-000066 |
Track record
25 reports on MESO
6 of 14 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
- Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
- Oct 29, 202618d ago 6-K Bullish 6/10 No price data
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
- Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
- Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
- Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
- Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
- Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers